Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Daily multivitamin showed no clear difference in mean number of new lesions compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.41 [-1.85, 1.03]
1 study
GRADE not reported
Duration of episodes · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Daily multivitamin showed no clear difference in duration of episodes compared with placebo; GRADE not reported.
1 finding from 1 review
MD -0.33 [-2.06, 1.40]
1 study
GRADE not reported
Change in ADAS‐Cog · people with Alzheimer's disease
1 finding from 1 review
Number of participants experiencing any serious adverse events · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Deaths Number of deaths · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in deaths Number of deaths compared with placebo (moderate certainty).
1 finding from 1 review
Activities of daily living · people with Alzheimer's disease
1 finding from 1 review
Progression to Alzheimer's disease Number of people progressing to AD · MCI
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in progression to Alzheimer's disease Number of people progressing to AD compared with placebo (moderate certainty).
1 finding from 1 review
Change in ADAS‐Cog · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing any serious adverse events · MCI
1 finding from 1 review
Death Number of deaths over 36 months · MCI
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in death Number of deaths over 36 months compared with placebo (moderate certainty).
1 finding from 1 review
Activities of daily living · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with active control (moderate certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with active control (low certainty).
1 finding from 1 review